News

Daily Pill Shows Promise in Slowing Type 1 Diabetes

October 8, 2025
Less than a minute


A 2-year follow-up of the randomized, placebo-controlled BANDIT trial shows that stopping baricitinib leads to a loss of therapeutic benefit, supporting its evaluation in earlier stages of type 1 diabetes to determine whether it can prevent or delay clinical onset. In 2023, researchers in Australia launched the pioneering BANDIT (Baricitinib in New Onset Type 1 […]

Source link

Related posts:

  1. New quintuple agonist shows promise for treating obesity and type 2 diabetes
  2. Mitochondrial protein misfolding found to kill pancreatic cells in type 2 diabetes
  3. Sugar layer on beta cells prevents immune system from causing type 1 diabetes
  4. New antibody cocktail shows promise for treating multiple strains of flu
See also  Study shows people overestimate hill steepness based on their eye level
Tags
October 8, 2025
Less than a minute
Photo of Digit

Digit

Digit is a versatile content creator with expertise in Health, Technology, Movies, and News. With over 7 years of experience, he delivers well-researched, engaging, and insightful articles that inform and entertain readers. Passionate about keeping his audience updated with accurate and relevant information, Digit combines factual reporting with actionable insights. Follow his latest updates and analyses on DigitPatrox.
Back to top button
close